# Study of Canakinumab in Patients With Myelofibrosis

> **NCT05467800** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **John Mascarenhas** · enrollment: 14 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- ET-MF
- Post-polycythemia Vera Related Myelofibrosis
- PV-MF

## Interventions

- **DRUG:** Canakinumab

## Key facts

- **NCT ID:** NCT05467800
- **Lead sponsor:** John Mascarenhas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-02
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05467800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05467800, "Study of Canakinumab in Patients With Myelofibrosis". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT05467800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*